[go: up one dir, main page]

WO2001012151A1 - Produit de soin pour la peau - Google Patents

Produit de soin pour la peau Download PDF

Info

Publication number
WO2001012151A1
WO2001012151A1 PCT/GB2000/003083 GB0003083W WO0112151A1 WO 2001012151 A1 WO2001012151 A1 WO 2001012151A1 GB 0003083 W GB0003083 W GB 0003083W WO 0112151 A1 WO0112151 A1 WO 0112151A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
component
vitamin
skin
inhibitor
Prior art date
Application number
PCT/GB2000/003083
Other languages
English (en)
Inventor
Paul Rodney Clayton
Original Assignee
Paul Rodney Clayton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul Rodney Clayton filed Critical Paul Rodney Clayton
Priority to EP00951735A priority Critical patent/EP1207847A1/fr
Priority to AU64587/00A priority patent/AU6458700A/en
Publication of WO2001012151A1 publication Critical patent/WO2001012151A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29—Titanium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • This invention relates to a skin care product. At least some embodiments provide skin care products for delaying or preventing skin ageing. At least some embodiments improve the physical appearance of persons afflicted with skin ageing. The invention further provides a cosmetic method of improving the appearance of a person suffering from skin ageing.
  • Skin ageing appears to involve two pathways; extrinsic and intrinsic. Extrinsic factors are important. 80% or more of skin ageing may be due to extrinsic factors. A major extrinsic factor is photic ageing. Photic ageing is cumulative damage due to repeated exposure to the ionising radiation content of sunlight. Such ionising radiation is thought, but again we do not wish to be bound by this theory, to trigger the release of free radicals. The free radicals are thought to cause damage in a number of ways. Very high levels may cause acute cell death. This leads to sloughing of the skin and the loss of generative cells in the lower dermis. Lower levels of free radicals may cause DNA damage.
  • MMPs matrix metalloproteases
  • the extracellular matrix is subject to two competing processes; catabolism and anabolism, which may be categorised as tissue wear and renewal respectively.
  • catabolic process is slightly greater than the anabolic process, and there is a gradual nett loss of tissue integrity, which results in the gradual appearance of ageing.
  • a large part of the catabolic or damaging process is caused by free radical damage caused by exposure to light. Extensive exposure to sunlight increases the rate of catabolism, resulting in accelerated ageing. It follows therefore that skin appearance can be improved by either slowing photic ageing, or increasing the rate of tissue renewal, or preferably both.
  • a skin care composition for reducing the photic ageing of skin by degradation of extracellular matrix comprising: i) at least one inhibitor of catabolism of the extracellular matrix; and ii) at least one anabolic or pro-anabolic factor for the extracellular matrix.
  • a cosmetic method of improving the appearance of a mammal afflicted with photic skin ageing comprising administering to the afflicted mammal the skin care composition of the invention.
  • compositions of the invention can include inhibitors of catabolism.
  • Catabolism inhibitors fall into several classes.
  • the invention may provide one or more members of one or more classes.
  • UV-blocking agent UV-blocking agents reduce the amount of high energy radiation reaching the skin. Since a reduced amount of radiation reaches the skin the potential for damage is reduced.
  • suitable UV- blocking agents include metal oxides such as titanium dioxide and zinc oxide which are opaque to a wide range of wavelengths and unsaturated compounds which have strong UV absorbency such as esters of cinnamic acid. The UV blocking agent will generally be applied topically.
  • Free radical quenchers destroy free radicals before substantial damage occurs.
  • the free radical quenchers fall into two sub-groups.
  • the first such as vitamin E, and carotenoids such as ⁇ -carotene and lycopene are lypophilic and thus tend to penetrate the dermis.
  • the second sub-group such as vitamin C are hydrophilic and tend to be most effective in extracellular fluids.
  • the free radical quenchers can be applied topically, orally or both.
  • MMP Inhibitors Free radicals may promote the release of MMPs which cause inflammation and hence damage.
  • Some embodiments of the invention comprise MMP inhibitors. Examples include flavonoids such as those obtain from bilberry, elderberry or chokeberry. These flavonoids may also inhibit glycosylation of macromolecules which may also be implanted in degeneration of the extracellular matrix. These materials may be administered orally or topically or both.
  • Anti-inflammatories include flavonoids such as those obtain from bilberry, elderberry or chokeberry. These flavonoids may also inhibit glycosylation of macromolecules which may also be
  • Anti-inflammatories are thought to reduce the damage caused by MMPs.
  • fatty acids such as omega 3 polyunsaturated fatty acids and cis- linoleic acid.
  • Purified fatty acids may be used but relatively impure forms such as certain fish oil or preferably plant oils may be used instead.
  • Application may be oral, topical or both.
  • the inhibitor In view of the large number of proteases in the body it is generally preferred to apply the inhibitor topically. However in the case of the Birket-Bowman protease inhibitor and other inhibitors which are present in foods, and which are frequently ingested, oral application may be preferable.
  • the above components alone or in conjunction may reduce the rate of photic ageing.
  • At lease some embodiments of the invention seek to enhance the rate of microfibre formation. It is believed that in many people microfibre formation is reduced due to micronutrient deficiency. Consequently administration of the micronutrients may enhance formation of micro fibres in the extracellular matrix.
  • Collagen formation may be stimulated by oral administration of vitamin C, vitamin B6, zinc ions and/or copper ions.
  • Formation of the aminosugar polymer component can be facilitated by glucosamine which will generally be administered orally as a physiologically acceptable salt such as the sulphate or, more preferably the hydrochloride.
  • glucosamine which will generally be administered orally as a physiologically acceptable salt such as the sulphate or, more preferably the hydrochloride.
  • manganese is considered to be an important co-factor in glucosamine polymerisation, manganese ions will also be included in the formulation.
  • a two part composition is employed.
  • a first part is for oral administration and a second for topical administration.
  • suitable compositions are as follows: Oral Components
  • Vitamin C 0.1 -5g, preferably 0.5-2g, especially 1 g in divided doses, more preferably in sustained release form; Vitamin B6 1 - 10 x RDI (Recommended Daily Input), preferably 5x RDI ;
  • Zinc in bioavailable form, e.g. as a chelate or organic or inorganic salt
  • -lOOmg preferably 5-20mg, especially lOmg; Copper (in bioavailable form, e.g. as a chelate or organic or inorganic alt) 1-lOOmg preferably 1-1 Omg, especially 5mg; Glucosamine (as hydrochloride) 0.1 - 1 Og preferably 0.5-2g, especially 1 g
  • Titanium dioxide finely divided or other UV filter Vitamin E - max permitted load Vitamin C (ascorbyl palmitate) - max permitted load OPC flavonoids
  • the oral component may be presented in powdered, tablet, encapsulated or liquid form and may optionally include colourings, flavourings and other materials.
  • the topical component will generally be presented in the form of a cream or lotion and may include colourings and perfumes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des produits de soin pour la peau permettant de réduire, de retarder ou d'éviter le vieillissement cutané. Ces produits comprennent des formulations topiques et orales et contiennent au moins un inhibiteur du catabolisme de la matrice extracellulaire et au moins un facteur anabolisant ou pro-anabolisant pour la matrice extracellulaire.
PCT/GB2000/003083 1999-08-12 2000-08-10 Produit de soin pour la peau WO2001012151A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00951735A EP1207847A1 (fr) 1999-08-12 2000-08-10 Produit de soin pour la peau
AU64587/00A AU6458700A (en) 1999-08-12 2000-08-10 Skin care product

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9919079.5 1999-08-12
GBGB9919079.5A GB9919079D0 (en) 1999-08-12 1999-08-12 Skin care product

Publications (1)

Publication Number Publication Date
WO2001012151A1 true WO2001012151A1 (fr) 2001-02-22

Family

ID=10859055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003083 WO2001012151A1 (fr) 1999-08-12 2000-08-10 Produit de soin pour la peau

Country Status (4)

Country Link
EP (1) EP1207847A1 (fr)
AU (1) AU6458700A (fr)
GB (2) GB9919079D0 (fr)
WO (1) WO2001012151A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10126396A1 (de) * 2001-05-31 2002-12-05 Beiersdorf Ag Verwendung von Glucosamin zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter und trockener Haut
EP1314420A1 (fr) * 2001-11-23 2003-05-28 Cognis Iberia, S.L. Compositions contre le vieillissement
WO2006022723A1 (fr) * 2004-08-18 2006-03-02 The Procter & Gamble Company Moyen pour ameliorer l'aspect des cheveux et des ongles chez les mammiferes
WO2004068970A3 (fr) * 2003-01-31 2006-03-09 Procter & Gamble Moyen pour ameliorer l'aspect de tissus keratiniques de mammiferes

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217690B2 (en) 2003-10-07 2007-05-15 Kimberly-Clark Worldwide, Inc. Compositions of sunflower trypsin inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694692A1 (fr) * 1992-08-13 1994-02-18 Thorel Jean Noel Préparation cosmétique de nutrition de la peau.
FR2704390A1 (fr) * 1993-04-29 1994-11-04 Boiron Complément nutritionnel absorbable per-os destiné à améliorer la peau.
CN1120931A (zh) * 1995-06-30 1996-04-24 张漪� 一种美容保健护肤品
US5658580A (en) * 1993-09-09 1997-08-19 Chanel, Inc. Skin cream composition
FR2746008A1 (fr) * 1996-03-14 1997-09-19 Thorel Jean Noel Composition a usage topique anti-vieillissement
JPH11124311A (ja) * 1997-10-20 1999-05-11 Shiseido Co Ltd 光毒性抑制剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU87145A1 (fr) * 1988-02-26 1989-09-20 Oreal Methode pour ameliorer l'aspect esthetique de la peau a l'aide de melanges polyvitaminiques
US5698206A (en) * 1996-12-05 1997-12-16 Swedish Herbal Systems, Inc. Topical composition for the treatment of spider veins
TWI234467B (en) * 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
AUPP229598A0 (en) * 1998-03-11 1998-04-09 Oldfield Family Holdings Pty Limited Treatment of sunburn

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694692A1 (fr) * 1992-08-13 1994-02-18 Thorel Jean Noel Préparation cosmétique de nutrition de la peau.
FR2704390A1 (fr) * 1993-04-29 1994-11-04 Boiron Complément nutritionnel absorbable per-os destiné à améliorer la peau.
US5658580A (en) * 1993-09-09 1997-08-19 Chanel, Inc. Skin cream composition
CN1120931A (zh) * 1995-06-30 1996-04-24 张漪� 一种美容保健护肤品
FR2746008A1 (fr) * 1996-03-14 1997-09-19 Thorel Jean Noel Composition a usage topique anti-vieillissement
JPH11124311A (ja) * 1997-10-20 1999-05-11 Shiseido Co Ltd 光毒性抑制剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199745, Derwent World Patents Index; AN 1997-481089, XP002154016 *
DATABASE WPI Week 199929, Derwent World Patents Index; AN 1999-341587, XP002154015 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10126396A1 (de) * 2001-05-31 2002-12-05 Beiersdorf Ag Verwendung von Glucosamin zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter und trockener Haut
EP1314420A1 (fr) * 2001-11-23 2003-05-28 Cognis Iberia, S.L. Compositions contre le vieillissement
WO2003043595A1 (fr) * 2001-11-23 2003-05-30 Cognis Iberia, S.L. Agents anti-vieillissement
WO2004068970A3 (fr) * 2003-01-31 2006-03-09 Procter & Gamble Moyen pour ameliorer l'aspect de tissus keratiniques de mammiferes
WO2006022723A1 (fr) * 2004-08-18 2006-03-02 The Procter & Gamble Company Moyen pour ameliorer l'aspect des cheveux et des ongles chez les mammiferes

Also Published As

Publication number Publication date
EP1207847A1 (fr) 2002-05-29
GB0019702D0 (en) 2000-09-27
AU6458700A (en) 2001-03-13
GB9919079D0 (en) 1999-10-13
GB2355193A (en) 2001-04-18

Similar Documents

Publication Publication Date Title
RU2320362C2 (ru) Местные фармацевтические композиции, содержащие проантоцианидины, для лечения дерматитов
US6800292B1 (en) Pomegranate fruit extract compositions for treating dermatological disorders
US6630163B1 (en) Method of treating dermatological disorders with fruit extracts
AU2009210455B2 (en) Improved skin brightening compositions
WO2000064472A1 (fr) Methodes de traitement de troubles dermatologiques au moyen d'extraits de fruits et compositions correspondantes
KR20020040670A (ko) 피부 지질 장벽 기능 증진용 조성물
US20060024339A1 (en) Methods of managing the redness associated with a dermatological condition
EP3090781A1 (fr) Composition anti-âge avec des extraits de plantes
JP2010502700A (ja) アクネを治療する医薬品、加齢および日焼けの症状を回復する医薬品、及び、これを用いた方法
Puizina-Ivić et al. Modern approach to topical treatment of aging skin
JP2009221154A (ja) インタ−ロイキン−６産生抑制剤
EP1207847A1 (fr) Produit de soin pour la peau
EP3643293A1 (fr) Concentré à base d'huile d'olive et préparation topique pour soins et réparation de la peau comprenant ledit concentré
CN104434642A (zh) 一种晒后修护美白保湿凝露及其制备方法
Salavkar et al. Antioxidants in skin ageing –Future of dermatology
Grunebaum et al. Nonprescription topical treatments for skin rejuvenation
KR101509603B1 (ko) 미백용 또는 항노화용 피부 외용제 조성물
KR102801893B1 (ko) 나노화된 벌화분 추출물을 유효성분으로 포함하는 여드름 치료용 조성물
Burke Antiaging Regimens
CN115154344A (zh) 一种晒后修护和提亮肤色的羟基酸组合物及其应用
JP2007204396A (ja) マトリックスメタロプロテアーゼ−９及びエンドセリン−１の産生抑制剤、並びにその産生抑制剤を配合した炎症後色素沈着の予防・改善剤、化粧料
EP1578433B1 (fr) Utilisation d'extrait de pothomorphe umbellata et gel composition a base d'extrait de pothomorphe umbellata
JP3955103B2 (ja) 損傷を与えたｒｎａ断片を含むサンスクリーン組成物
BG4932U1 (bg) Антиоксидантен състав
KR100563673B1 (ko) 피부 주름 개선 및 피부 주름 생성 억제용 건강기능식품

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000951735

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000951735

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000951735

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP